Category: Corona Virus Vaccine

Many symptoms of COVID-19 have surfaced in the years since cases of the SARS-CoV-2 virus surfaced in late 2019. Although respiratory symptoms have received the most attention throughout the pandemic, eye pain is also a common complaint.

Eye pain, burning, and soreness can all develop with a COVID-19 infection. This article will explore why these issues develop, what eye pain symptoms you could have, and what a COVID-10-related eye problem means for your overall health.

Jelena Stanojkovic / Getty Images

You may develop eye pain with a COVID-19 infection for a few reasons.

On the simplest level, medications designed to help reduce congestion or treat cough can have a drying effect that can impact your eyes. Headaches, sinus pressure, and coughing or sneezing can also lead to eye symptoms like irritation, soreness, watering, or dryness.

Eye pain usually appears during the first week of a COVID-19 infection but can increase or appear later if your infection becomes more severe. Some of the most common eye-related complaints with a COVID-19 infection include:

The eye is a known entry point for the virus. COVID-related eye infections like conjunctivitis (pink eye) have been documented throughout the pandemic. Some evidence suggests eye secretions or drainage can transmit the virus to others.

Some studies have suggested that the proximity of the eyes to nasal passages can also increase eye symptoms, especially since the viral load (measurement of the amount of virus in the body) of SARS-CoV-2 in the nasal passages is usually higher than in the throat.

Plus, headaches, nasal congestion or drainage, fever, and other symptoms of a COVID-19 infection can also cause head pain or pressure that can affect your eyes.

There also may be a connection between neurological and immune-related complications of COVID-19 and eye pain. COVID-19 infections have been found to increase your risk of neurological disorders associated with inflammation or nerve damage.

These viral infections have also been linked to autoimmune reactions (in which your immune system attacks your own cells), which could increase sensitivity in different areas of the body or even cause your own tissues to work against themselves.

Several versions (variants) of the virus that causes COVID-19 have appeared since it was first recognized. While there are some consistent symptoms across all variants, symptoms can vary among variants.

For example, losing your sense of smell is a symptom associated most with the Delta variant, while congestion and headache were more prominent with the Omicron variant of the virus. The JN.1 variant circulating in early 2024 more frequently featured gastrointestinal symptoms like diarrhea.

How COVID affects your eyes and vision may depend on the variant you were infected with and any previous health or vision problems you had before the infection.

Dryness, irritation, and soreness in your eyes with an active viral infection aren't that uncommon, but some lasting eye symptoms have been included in lists of long COVID symptoms.

"Long COVID" is the term for the symptoms and ongoing complications people may experience long after their COVID-19 infection is considered resolved.

Inflammation is common with most forms of COVID-19, and ongoing eye problems are thought to stem from continued inflammation, nerve damage, and changes to your immune system after your acute illness.

Some documented eye problems that have been linked to long COVID include the following:

Some of these eye problems can affect your vision and result in permanent damage.

Most eye symptoms associated with COVID-19 resolve on their own. One study found that eye symptoms with a COVID infection went away within two weeks the active infection resolving.

For ongoing symptoms that continue after the infection, it's important to schedule an appointment with an eye care provider to rule out other conditions or complications.

Issues like dry eye, irritation, and even infection can be treated with things like eye drops, ointments, or antibiotics as recommended or prescribed by a healthcare provider. For more serious complications linked to blood clots that could affect or even destroy your vision, more intense treatments may be required.

One option for treating eye problems related to blood clots after a COVID-19 infection is intravenous medication that dissolves the clots, like Activase (alteplase). Even if the clot resolves, you could require ongoing treatment to address any permanent damage.

Generally, people who develop serious eye problems have severe forms of COVID-19 infection. Outside of the severity of the initial infection, COVID-related eye problems tend to happen more in people with preexisting conditions like:

In terms of your COVID-19 infection, it's important you see healthcare provider if your symptoms become severe, resulting in problems like:

For eye problems, specifically, over-the-counter lubricating eye drops and at-home remedies like a warm compress may help most.

Don't wait, though, if your symptoms become worse or you notice that your vision is being affected. Retinal bleeding and blood clots usually appear with a sudden total loss of vision without pain. They must be treated as a medical emergency to avoid permanent vision loss.

COVID-19 infections can appear with a wide range of symptoms, including eye pain. Eye pain, soreness, and irritation usually fade in a week or two as the infection resolves. However, some COVID-related problems can lead to more severe eye problems and even vision loss.

Call your healthcare provider to schedule a more in-depth evaluation if you have vision changes during or after your COVID-19 infection.

The information in this article is current as of the date listed, which means newer information may be available when you read this. For the most recent updates on COVID-19, visit our coronavirus news page.

More here:

COVID-19 and Eye Pain: What's the Link? - Verywell Health

Rates of new-onset autoimmune inflammatory rheumatic disease (AIRD) such as rheumatoid arthritis and systemic lupus erythematosus were significantly increased following bouts of COVID-19 in South Korea and Japan, researchers found.

With data from large repositories in the two countries, AIRD rates were 25% higher in South Korea (95% CI 18-31) and 79% greater in Japan (95% CI 77-82) among COVID-19 patients versus uninfected controls from the general population, according to Dong Keon Yon, MD, PhD, of Kyung Hee University in Seoul, and colleagues.

Absolute rates after COVID were 1.15% in Korea and 3.87% in Japan.

However, vaccination against SARS-CoV-2 reduced the likelihood of developing AIRD following breakthrough infection, except when those infections became severe, the researchers reported in Annals of Internal Medicine. In fact, severity of COVID-19 increased AIRD risks across the board.

Yon and colleagues stopped short of calling AIRD a form of "long COVID," in which fatigue, malaise, and respiratory symptoms typically predominate. What they did conclude was that AIRD appears to qualify as a long-term COVID-19 complication: AIRD development rates remained strongly elevated in both countries up to a year after infection, and beyond that in the Japanese data (HR 1.57 vs general population, 95% CI 1.50-1.64) though not in Korea.

The risk increase wasn't an artifact of COVID-19 patients having more contact with healthcare systems and thus heightened observation, the researchers emphasized. Their analyses also included comparisons between COVID-19 patients and people treated for influenza; AIRD rates were significantly greater in the COVID groups, by 30% in the Korean data and by 14% in Japan.

Other studies had examined rheumatologic disease rates following COVID-19, which also found increases in risk. But those studies didn't account for possible ascertainment bias, Yon and colleagues pointed out, nor did they look at vaccination's potential influence.

The new analysis used a case-control design. Korean national data included some 394,000 people with documented COVID-19 infection. Yon and colleagues selected about 177,000 for propensity matching; each was coupled with four uninfected (neither COVID nor influenza) individuals in the general population, for a total of 676,000 controls. The comparison between COVID and flu patients included 95,000 in each group. Matching covered numerous health-related and sociodemographic parameters at baseline. The Japanese cohorts included 961,000 COVID-19 patients to be compared with 1.6 million uninfected people; for COVID versus influenza, the group sizes were 115,000 and 110,000, respectively.

Severity of COVID-19 was established through records of treatments such as intensive care admission and extracorporeal membrane oxygenation. Vaccination status, including the number of vaccine doses, was also contained in the data. Yon and colleagues identified AIRD cases in two categories: inflammatory arthritis, comprising rheumatoid and psoriatic arthritis and spondyloarthritis; and connective tissue diseases, which included lupus, Sjgren's syndrome, systemic sclerosis, polymyalgia rheumatica, mixed connective tissue disease, dermatomyositis, polymyositis, polyarteritis nodosa, and vasculitis.

Not all the results were similar between countries or in the comparisons between COVID and influenza. For example, no elevation in rates of inflammatory arthritis was seen in Korea with respect to the general population (HR 0.90, 95% CI 0.65-1.24), yet in Japan the risk was doubled (HR 2.02, 95% CI 1.96-2.07). On the other hand, Koreans with COVID went on to face substantially greater risk for inflammatory arthritis than did those with flu, albeit without statistical significance (HR 1.92, 95% CI 0.34-3.65), while in Japan the rates hardly differed (HR 1.07, 95% CI 1.03-1.13).

Patterns were more consistent for connective tissue diseases, with rates significantly higher after COVID-19 in both types of comparison in both countries.

Elevations in AIRD rates were apparent early, by 26% in Korea and 87% in Japan relative to general population controls within the first 6 months after infection, and by 33% and 44% in Korea and Japan, respectively, relative to influenza patients. The elevations shrank a little during the period 6 to 12 months after infection. After 1 year, there was no difference in either country between previous COVID and flu patients, and only in Japan did the elevation relative to the general population persist.

Yon and colleagues also looked at the influence of COVID severity on AIRD rates, both overall and with respect to vaccination status. Relative to uninfected controls, AIRD rates in Korea were 22% greater in patients with mild COVID, but 42% higher in moderate-severe cases. AIRD was also less frequent in COVID survivors who had been vaccinated, with hazard ratios of 0.59 after one dose and 0.42 after two (both P<0.05).

Vaccination did not, however, protect fully against AIRD when COVID was rated as moderate-severe (HR 1.30 vs uninfected controls).

The researchers cited a number of limitations to the analysis, including the reliance on administrative data, the possibility of unmeasured confounders, and the restriction to East Asian populations. Also, the data were recorded prior to 2022 and thus predated the broad spread of the Omicron SARS-CoV-2 variant. Sample sizes for some types of AIRD were probably too small to yield meaningful results.

John Gever was Managing Editor from 2014 to 2021; he is now a regular contributor.

Disclosures

The National Research Foundation of Korea funded the study.

Authors declared they had no relevant relationships with commercial entities.

Primary Source

Annals of Internal Medicine

Source Reference: Kim MS, et al "Long-term autoimmune inflammatory rheumatic outcomes of COVID-19" Ann Intern Med 2024; DOI: 10.7326/M23-1831.

See the original post here:

COVID-19 Tied to Increased Risk for Rheumatic Disease - Medpage Today

In a recent study published in the New England Journal of Medicine, researchers assessed cognitive functioning among adults with varying levels of persistence of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in England.

Their results suggest that COVID-19 is associated with measurable cognitive deficits, which may persist in the long term.

Study: Cognition and Memory after Covid-19 in a Large Community Sample. Image Credit:Berit Kessler/ Shutterstock

The first documented cases of brain fog, with symptoms such as poor memory, impaired concentration, and difficulty thinking, emerged as early as 2020, indicating that COVID-19 could have long-term cognitive impacts.

Though the phenomenon is well-known, what is lacking is information on how it may persist and which aspects of cognitive functioning are most affected.

In this study, researchers hypothesized that cognitive deficits after the onset of COVID-19 should be quantifiable and associated with covariates related to illness severity and duration.

Their second hypothesis was that individuals with prolonged COVID-19 symptoms should show more observable memory and executive function impairment, including brain fog and poor memory.

They conducted a cohort-based study tracking the prevalence of SARS-CoV-2 infection among 3,099,386 individuals aged over 18 years. Of these, 800,000 people were invited to complete a cognitive assessment and follow-up survey.

To be included, they should have received a positive result on a SARS-CoV-2 diagnostic test or suspected that they had COVID-19 and experienced symptoms for 12 weeks or more. Additionally, unvaccinated people with SARS-CoV-2 immunoglobulin-G antibodies and other randomly selected people from the full sample were included.

The cognitive assessment tested immediate and spatial working memory, verbal analogical reasoning, two-dimensional mental manipulation, spatial planning, word definitions, delayed memory, and information sampling. For each domain, participants were scored on accuracy; secondary information was collected on types of errors and response times.

Individuals were categorized into six groups based on SARS-CoV-2 duration. The first category included those who had never experienced an infection or had an unconfirmed one; all other categories required a positive test result.

People in the second category had asymptomatic infections, those in the third had short COVID-19 that resolved in four weeks or less, and those in the fourth had symptoms that resolved in less than 12 weeks. To be in the fifth category, individuals had symptoms that persisted for more than 12 weeks; those in the sixth had persistent symptoms continuing until the cognitive assessments.

Researchers assessed nonresponse bias to examine which factors were associated with accessing and completing the cognitive assessment. Linear regressions, factor analysis, and propensity-score matching (PSM) were used to analyze the data. Sensitivity analyses were also conducted to test the validity and robustness of the results.

Of the 800,000 people invited to participate, 34.6% completed the questionnaire, with 141,583 completing at least one cognitive testing task and 112,964 completing all eight.

Among individuals infected with SARS-CoV-2 once, being infected earlier during the pandemic was associated with greater decreases in the overall cognitive score compared to those infected later. However, the gap narrowed after adjusting for the severity of the illness.

On average, people who were ill for longer, were hospitalized, or were infected early on in the pandemic had lower overall cognitive scores than those who had never had COVID-19.

Multivariate regression results indicated that people infected during the initial stages (when the original virus or alpha variant dominated) showed higher cognitive functioning decreases than those infected with the alpha or omicron variants.

Similarly, greater decreases were seen in people with persistent and unresolved symptoms compared to those who never had COVID-19 and among people who were hospitalized compared to those who were not.

The PSM analysis showed similar trends; cognitive advantages were observed based on vaccination status, with people who received two or more doses performing best. There was, however, no significant difference based on which vaccine was taken.

This large-sample community-based study suggests that COVID-19 may be associated with long-term and quantifiable cognitive deficits. However, people infected with more recent variants may experience more negligible effects on cognitive functioning.

This could be because earlier strains of SARS-CoV-2 were dominant at a time when effective treatments were not available, and the health system faced heavy burdens. Repeated infections do not appear to have any effect, but vaccination (particularly two or more doses) may provide small cognitive advantages.

Limitations of this study include the possibility of participant self-selection bias and reliance on self-reported data. Certain groups were overrepresented in the sample, including White persons and women; younger people and certain underprivileged groups were underrepresented.

Further studies are required to provide information on the longer-term implications of these findings.

Journal reference:

Here is the original post:

COVID-19 linked to long-lasting cognitive deficits, study finds - News-Medical.Net

Its been four years since the COVID-19 pandemic started, and a lot has changed. Life has mostly gone back to normal, and many treat the Coronavirus like the common cold. Now, the Centers for Disease Control and Prevention (CDC) has made a big change in COVID-19 protocol recommendations for 2024.

The new guidance throws out the previous five-day isolation recommendation in favor of a more relaxed approach. The CDC is also now lumping COVID-19 recommendations with those of the flu and RSV.

CDC is making updates to the recommendations now because the U.S. is seeing far fewer hospitalizations and deaths associated with COVID-19 and because we have more tools than ever to combat flu, COVID, and RSV, the organization said in a statement online.

The CDC also stressed the importance of core prevention steps and strategies to lower the risk of getting seriously ill from a respiratory virus, including staying up to date with vaccines, practicing good hand hygiene, and focusing on cleaner air by trying to bring in more fresh outside air, purifying indoor air (by using the best air purifiers), and gathering outside instead of inside.

But a lot of people understandably want to know what they should now do when they get sick with COVID-19. Heres what the CDC says, along with how infectious disease doctors feel about the changes.

If you test positive for COVID-19 or have respiratory virus symptoms (like a fever, chills, fatigue, cough, runny nose, and/or headache) that arent explained by another cause, the CDC recommends that you stay home and away from others. During that isolation period, it's best to wear a high-quality, well-fitting mask, like an N95 mask, when you need to be around others.

The CDC says that you can go back to your normal activities when youve been fever-free without the use of fever-reducing medication, and feeling better for at least 24 hours.

When you go back to your normal activities, the CDC recommends that you take added precaution for the next five days, like using masks, practicing physical distancing, and testing yourself when youll be around other people indoors.

Keep in mind that you may still be able to spread the virus that made you sick, even if you are feeling better, the CDC says. You are likely to be less contagious at this time, depending on factors like how long you were sick or how sick you were.

If you develop a fever or start to feel worse after youve gone back to your normal activities, the CDC recommends that you stay home and away from others for at least 24 hours until your symptoms get better and you havent had a fever without the help of fever-reducing medication. Once you go back to your usual routine, the CDC recommends again taking extra precautions for the next five days.

If youre at high risk for serious complications from COVID-19, are immunocompromised, or are over 65, its a good idea to contact your doctor to see if you may benefit from taking an antiviral medication like Paxlovid, says William Schaffner, M.D., an infectious disease specialist and professor at the Vanderbilt University School of Medicine.

Infectious disease experts are supportive of the CDCs change. Its a good thing and will be welcomed by the general public, which has largely been doing this on their own for some time, Dr. Schaffner says. Dr. Schaffner says he and several other people in the infectious disease community have been urging the CDC to revise the guidelines for a while. The CDC waited a bit to make sure that the current trends in COVID really were sustained, he says.

Infectious disease expert Amesh A. Adalja, M.D., senior scholar at the Johns Hopkins Center for Health Security, says hes supportive of the new guidelines. They reflect the fact that the context of COVID-19the respiratory virus infection for which we have the most toolshas changed, he says. Similar updates to the guidelines were made in California, Oregon, and many other countries and, in that respect, the CDC was lagging.

Dr. Schaffner points out that, while people continue to get seriously ill and die from COVID-19, thats no longer the case for most of the American public. Well over 90% of the U.S. population has had some experience with COVID, through infection or vaccination, or both, he says. The virus itself is not as virulent or severe as it once was, and it appears to produce somewhat milder disease now."

Shortening the isolation period should have no measurable impact on how much COVID-19 spreads in the general population, Dr. Schaffner says.

To protect others around you if you test positive for COVID-19, the CDC recommends isolatingincluding from members of your householduntil youve been fever-free without the help of fever-reducing medications for 24 hours. This is especially important if youre around anyone who is at high risk of serious disease, Dr. Schaffner says.

Masking up when you need to be around others and practicing careful hand hygiene can also help limit the spread, the CDC says. Its also a good idea to take steps to create cleaner indoor air, like opening doors and windows and using exhaust fans, per the CDC. You can even try adding an air purifier to your space.

Dr. Schaffner stresses the importance of getting the COVID-19 vaccine when youre healthy as well. So many people have not taken advantage of the updated vaccine, he says. But the vast majority of people being hospitalized today because of COVID are unvaccinated.

Korin Miller is a freelance writer specializing in general wellness, sexual health and relationships, and lifestyle trends, with work appearing in Mens Health, Womens Health, Self, Glamour, and more. She has a masters degree from American University, lives by the beach, and hopes to own a teacup pig and taco truck one day.

Follow this link:

Current CDC COVID Guidelines 2024: What to Do if You Test Positive - Prevention Magazine

A bold move to rip up intellectual property protections for COVID-19 vaccines appears to have been quietly dropped, after the World Trade Organization (WTO) opted not to extend the measure.

At the height of the COVID-19 pandemic, many commentators argued for a radical change to global licensing rules, compelled by the urgency of the situation and the need to broaden access to newly-available vaccines.

This led to the so-called Trade-Related Aspects

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

Continued here:

Not needed after all, WTO drops the COVID-19 TRIPS waiver - The Pharma Letter

Students and staff who contract COVID-19 no longer need to automatically isolate for five days, according to new guidance issued this week by the Centers for Disease Control and Prevention.

The CDC still recommends that those with the coronavirus stay home from school or work for at least a full day after their symptoms improve and they no longer have a fever for at least 24 hours. The CDC continues to recommend those infected wash their hands, use masks, and keep physical distance from others where possible for at least five days.

According to CDC Director Mandy Cohen, the agency changed its recommendations because 98 percent of Americans now have at least partial COVID immunity and there are more effective treatments for the illness.

The guidance unifies prevention strategies for three common respiratory diseases that have been surging in schools: COVID-19, influenza, and respiratory syncytial virus, or RSV. It plans to release additional guidance for schools by the end of the school year including strategies to control the spread of other illnesses such as norovirus and strep pharyngitis.

The CDC continues to call for people to get immunized, practice good hygiene, and install updated indoor air-quality systems.

The bottom line is that when people follow these actionable recommendations to avoid getting sick, and to protect themselves and others if they do get sick, it will help limit the spread of respiratory viruses, and that will mean fewer people who experience severe illness, says Dr. Demetre Daskalakis, director of the CDCs National Center for Immunization and Respiratory Diseases, in a statement. The center focuses on research and monitoring of illnesses like COVID and the flu.

As coronavirus outbreaks have become less frequent and schools continue to work to help students recover academically from lost instruction during the pandemic, most districts have rolled back most or all quarantine rules enacted during the pandemic, including masking and mandated isolation. In a nationally representative survey by the EdWeek Research Center in January, more than 6 in 10 educators say they never wear a face mask at school, and only 3 percent say they mask nearly every day.

I dont think this will be a big change for most schools, said Kate King, the president of the National Association of School Nurses.

King, a school nurse at World Language Middle School in Columbus, Ohio, said her school still offers free masks and allows parents to keep their children home if they are sick, but COVID-related absences are considered parent-excused rather than medically excused without a doctors note.

However, the pandemic has led to lasting behavior changes at schools that may help cut down on outbreaks of all kinds, King said.

"[The pandemic] has really raised awareness of hand washing and what we call respiratory etiquette'coughing and sneezing in your elbow rather than in your hands, use of hand sanitizer, and hand washing, King said. I do see both students and staffwhen they feel bad, when they have a cold or a runny nosethey do wear masks for that duration. So, I dont think its huge, but I do think there is more awareness.

The CDC also urged schools to do more to encourage students and staff to get updated immunizations for flu, COVID-19, and, if available, a new RSV vaccine still being rolled out.

Vaccination rates have fallen for school-age children for both flu and coronavirus in the 2023-24 season. Just over half of children and adolescents have gotten a flu immunization this season, down from 53 percent last season and nearly 60 percent before the pandemic in 2020. COVID vaccination rates are even lower. While about a third of children 5-11 and nearly 60 percent of those ages 12-17 completed the initial two-dose vaccination before the end of the 2022-23 school year, only about 13 percent of school-age children have received the updated booster in 2023-24.

School-based immunization efforts have continued since the pandemic, King said. Our real focus as school nurses is school-located vaccine clinics, she said. We know that that is the key to preventing all of these diseases ... and school is the best place. Parents trust schools; they dont have to miss work, and kids are already here.

Here is the original post:

CDC Recommends Shorter Isolation Period for COVID-19 - Education Week

The US governments free at-home Covid-19 test program will be suspended Friday, according to the Administration for Strategic Preparedness and Response.

(CNN) The US governments free at-home Covid-19 test program will be suspended Friday, according to the Administration for Strategic Preparedness and Response.

Since November, residential households in the US have been able to submit an order through Covidtests.gov for four individual rapid antigen tests. All orders placed on or before Friday will be fulfilled, according to ASPR, an operating division of the US Department of Health and Human Services.

ASPR has delivered over 1.8 billion free COVID-19 tests to the American people throughCOVIDTests.gov and direct distribution pathways and will continue distributing millions of tests per week to long-term care facilities, food banks, health centers, and schools, an ASPR spokesperson said in a statement Tuesday.

The decision to suspend the programs sixth run comes amid falling Covid-19 cases as the nations respiratory virus season winds down, according to the agency.

Last month, the US Centers for Disease Control and Prevention said that the worst of the season may be over but warned that Covid-19 levels remain elevated across the country.

While the respiratory virus season is likely past its peak, it is definitely not over, the agency said. There is still a lot of respiratory virus activity, so its not time to let our guard down.

Rates of Covid-19-related hospitalizations remain elevated but are decreasing in some parts of the country, CDC data shows. Still, thousands of people are being hospitalized with Covid-19 each week: more than 17,000 during the week ending February 24, according to the CDC.

An ASPR spokesperson says the agency reserves the right to reopen the testing program if needed.

The government previously suspended the rapid test distribution program in May after the end of the Covid-19 public health emergency. It was reopened September 25.

Residents who havent placed an order since then can now place two, which will provide eight tests in total, according to the US Postal Service. Each order includesfour rapid antigen Covid-19 tests.

These tests can be taken at home and can be used regardless of whether someone has symptoms. The tests should work through the end of the year; some of the dates on the labels may show that theyre expired, but the US Food and Drug Administration hasextended those dates.

The CDCrecommends that people testif they have any Covid-19-like symptoms including a sore throat, a runny nose, loss of smell or taste or a fever.

People may also want to test before theyre going to be a part of a large event, like a concert or a conference, particularly if they arent up-to-date on their vaccines. Antiviral medications are available to treat both Covid-19 and flu, and testing can help determine which is needed.

More information on free testing resources is available on the Covidtests.gov site or at 1-800-232-0233 (TTY 1-888-720-7489).

CNNS Deidre McPhillips contributed to this report.

Correction: A previous version of this story incorrectly described ASPR.

The-CNN-Wire & 2024 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.

Read more:

Free home Covid-19 test program to be suspended this week - WTOP

Updated CDC recommendations address the prevention of respiratory viruses, emphasizing vaccines, hygiene, and air quality. The guidance is tailored to the current COVID-19 context and aims to protect vulnerable groups. Credit: James Gathany, Centers for Disease Control and Prevention

The CDC has issued new guidance for combating respiratory viruses, highlighting vaccination, hygiene, and air quality improvements. It focuses on reducing the spread of illnesses and protecting high-risk populations, adapting to the evolving COVID-19 situation.

On March 1, the CDC released updated recommendations for how people can protect themselves and their communities from respiratory viruses, including COVID-19. The new guidance brings a unified approach to addressing risks from a range of common respiratory viral illnesses, such as COVID-19, flu, and RSV, which can cause significant health impacts and strain on hospitals and healthcare workers. CDC is making updates to the recommendations now because the U.S. is seeing far fewer hospitalizations and deaths associated with COVID-19 and because we have more tools than ever to combat flu, COVID, and RSV.

Todays announcement reflects the progress we have made in protecting against severe illness from COVID-19, said CDC Director Dr. Mandy Cohen. However, we still must use the commonsense solutions we know work to protect ourselves and others from serious illness from respiratory virusesthis includes vaccination, treatment, and staying home when we get sick.

As part of the guidance, CDC provides active recommendations on core prevention steps and strategies:

When people get sick with a respiratory virus, the updated guidance recommends that they stay home and away from others. For people with COVID-19 and influenza, treatment is available and can lessen symptoms and lower the risk of severe illness. The recommendations suggest returning to normal activities when, for at least 24 hours, symptoms are improving overall, and if a fever was present, it has been gone without use of a fever-reducing medication.

Once people resume normal activities, they are encouraged to take additional prevention strategies for the next 5 days to curb disease spread, such as taking more steps for cleaner air, enhancing hygiene practices, wearing a well-fitting mask, keeping a distance from others, and/or getting tested for respiratory viruses. Enhanced precautions are especially important to protect those most at risk for severe illness, including those over 65 and people with weakened immune systems. CDCs updated guidance reflects how the circumstances around COVID-19 in particular have changed. While it remains a threat, today it is far less likely to cause severe illness because of widespread immunity and improved tools to prevent and treat the disease. Importantly, states and countries that have already adjusted recommended isolation times have not seen increased hospitalizations or deaths related to COVID-19.

While every respiratory virus does not act the same, adopting a unified approach to limiting disease spread makes recommendations easier to follow and thus more likely to be adopted and does not rely on individuals to test for illness, a practice that data indicates is uneven.

The bottom line is that when people follow these actionable recommendations to avoid getting sick, and to protect themselves and others if they do get sick, it will help limit the spread of respiratory viruses, and that will mean fewer people who experience severe illness, National Center for Immunization and Respiratory Diseases Director Dr. Demetre Daskalakis said. That includes taking enhanced precautions that can help protect people who are at higher risk for getting seriously ill.

The updated guidance also includes specific sections with additional considerations for people who are at higher risk of severe illness from respiratory viruses, including people who are immunocompromised, people with disabilities, people who are or were recently pregnant, young children, and older adults. Respiratory viruses remain a public health threat. CDC will continue to focus efforts on ensuring the public has the information and tools to lower their risk or respiratory illness by protecting themselves, their families, and their communities.

This updated guidance is intended for community settings. There are no changes to respiratory virus guidance for healthcare settings.

See the original post here:

COVID-19, Flu, and RSV: CDC Updates and Simplifies Respiratory Virus Recommendations - SciTechDaily

Scientists in Germany were baffled after a 62-year-old man from Magdeburg claimed that he received more than 200 vaccine doses for Covid-19. Researchers at Friedrich-Alexander-Universitt Erlangen-Nrnberg (FAU) and Universittsklinikum Erlangen found about the man from newspaper reports and studied his immune response.

"We learned about his case via newspaper articles. We then contacted him and invited him to undergo various tests in Erlangen. He was very interested in doing so," said Dr Kilian Schober from the Institute of Microbiology Clinical Microbiology, Immunology and Hygiene in a press release. The release also stated, that the man from Germany received 217 vaccinations deliberately and for private reasons within 29 months.(Also Read: CDC shortens isolation time for COVID-19 patients in new guidelines)

"The individual has undergone various blood tests over recent years," explained Schober. "He gave us his permission to assess the results of these analyses. In some cases, samples had been frozen, and we were able to investigate these ourselves. We were also able to take blood samples ourselves when the man received a further vaccination during the study at his own insistence. We were able to use these samples to determine exactly how the immune system reacts to the vaccination."

According to the press release, the test subject had a high number of T-effector cells that can defend the body against Covid-19 infection. When compared to a control group of individuals who received three immunisations, the test subject had more T-effector cells. Furthermore, the researchers found that these effector cells were not fatigued and were similarly effective as those in the control group who had received the normal number of vaccinations. (Also Read: All about two rare Covid-19 vaccine side effects detected in a study)

"The number of memory cells was just as high in our test case as in the control group. Overall, we did not find any indication for a weaker immune response; rather, it was the contrary," explains Katharina Kocher, one of the leading authors of the study published in Lancet Infectious Diseases journal.

Additional testing revealed the man's immune system's ability to fight off other infections remained unchanged. Therefore, it appears that the immune system was 'not damaged' by overvaccination.

See original here:

German man claims to receive 217 Covid-19 vaccine doses, shocks researchers - Hindustan Times

This transcript has been edited for clarity.

Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson of the Yale School of Medicine.

In the early days of the pandemic, before we really understood what COVID was, two specialties in the hospital had a foreboding sense that something was very strange about this virus. The first was the pulmonologists, who noticed the striking levels of hypoxemia low oxygen in the blood and the rapidity with which patients who had previously been stable would crash in the intensive care unit.

The second, and I mark myself among this group, were the nephrologists. The dialysis machines stopped working right. I remember rounding on patients in the hospital who were on dialysis for kidney failure in the setting of severe COVID infection and seeing clots forming on the dialysis filters. Some patients could barely get in a full treatment because the filters would clog so quickly.

We knew it was worse than flu because of the mortality rates, but these oddities made us realize that it was different too not just a particularly nasty respiratory virus but one that had effects on the body that we hadn't really seen before.

That's why I've always been interested in studies that compare what happens to patients after COVID infection vs what happens to patients after other respiratory infections. This week, we'll look at an intriguing study that suggests that COVID may lead to autoimmune diseases like rheumatoid arthritis, lupus, and vasculitis.

The study appears in the Annals of Internal Medicine and is made possible by the universal electronic health record systems of South Korea and Japan, who collaborated to create a truly staggering cohort of more than 20 million individuals living in those countries from 2020 to 2021.

The exposure of interest? COVID infection, experienced by just under 5% of that cohort over the study period. (Remember, there was a time when COVID infections were relatively controlled, particularly in some countries.)

The researchers wanted to compare the risk for autoimmune disease among COVID-infected individuals against two control groups. The first control group was the general population. This is interesting but a difficult analysis, because people who become infected with COVID might be very different from the general population. The second control group was people infected with influenza. I like this a lot better; the risk factors for COVID and influenza are quite similar, and the fact that this group was diagnosed with flu means at least that they are getting medical care and are sort of "in the system," so to speak.

But it's not enough to simply identify these folks and see who ends up with more autoimmune disease. The authors used propensity score matching to pair individuals infected with COVID with individuals from the control groups who were very similar to them. I've talked about this strategy before, but the basic idea is that you build a model predicting the likelihood of infection with COVID, based on a slew of factors and the slew these authors used is pretty big, as shown below and then stick people with similar risk for COVID together, with one member of the pair having had COVID and the other having eluded it (at least for the study period).

After this statistical balancing, the authors looked at the risk for a variety of autoimmune diseases.

Compared with those infected with flu, those infected with COVID were more likely to be diagnosed with any autoimmune condition, connective tissue disease, and, in Japan at least, inflammatory arthritis.

The authors acknowledge that being diagnosed with a disease might not be the same as actually having the disease, so in another analysis they looked only at people who received treatment for the autoimmune conditions, and the signals were even stronger in that group.

This risk seemed to be highest in the 6 months following the COVID infection, which makes sense biologically if we think that the infection is somehow screwing up the immune system.

And the risk was similar with both COVID variants circulating at the time of the study.

The only factor that reduced the risk? You guessed it: vaccination. This is a particularly interesting finding because the exposure cohort was defined by having been infected with COVID. Therefore, the mechanism of protection is not prevention of infection; it's something else. Perhaps vaccination helps to get the immune system in a state to respond to COVID infection more appropriately?

Yes, this study is observational. We can't draw causal conclusions here. But it does reinforce my long-held belief that COVID is a weird virus, one with effects that are different from the respiratory viruses we are used to. I can't say for certain whether COVID causes immune system dysfunction that puts someone at risk for autoimmunity not from this study. But I can say it wouldn't surprise me.

F. Perry Wilson, MD, MSCE, is an associate professor of medicine and public health and director of Yale's Clinical and Translational Research Accelerator. His science communication work can be found in the Huffington Post, on NPR, and here on Medscape. He tweets @fperrywilson and his book, How Medicine Works and When It Doesn't, is available now.

Credits: Image 1: Centers for Disease Control and Prevention Image 2: Worldometer Image 3: Annals of Internal Medicine Image 4: F. Perry Wilson, MD, MSCE Image 5: F. Perry Wilson, MD, MSCE Image 6: F. Perry Wilson, MD, MSCE Image 7: F. Perry Wilson, MD, MSCE Image 8: F. Perry Wilson, MD, MSCE

Medscape2024WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: SARS CoV-2 Is a Very Weird Virus-Medscape-Mar04,2024.

Go here to see the original:

SARS CoV-2 Is a Very Weird Virus - Medscape